ArticleFrontiers in medicine2026
Serology and magnetically controlled capsule gastroscopy for opportunistic screening of high-risk events in gastric cancer development: a cross-sectional study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The feasibility of magnetically controlled capsule gastroscopy (MCCG) as an alternative diagnostic tool, along with a sequential serology-MCCG protocol, needs to be assessed for its effectiveness in detecting high-risk events associated with gastric cancer development. Methods: Health check-up records were collected between 2019 and 2020. Asymptomatic individuals underwent MCCG and relevant serologic examinations, which included tests for pepsinogen-I (PG-I), pepsinogen-II (PG-II), gastrin-17, carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9). The major outcomes from MCCG included tumors and high-risk events, specifically chronic atrophic gastritis (CAG), gastric ulcer, and gastric polyps. The detection rate of MCCG was estimated, and the predictive strength of serology for MCCG findings was analyzed. Results: A total of 1,432 eligible healthy individuals undergoing routine health check-ups were included. MCCG detected no tumors, but identified 114 cases with at least one high-risk event. The overall detection rate was 79.6 per 1,000 persons for all high-risk events with specific detection rates for CAG, ulcer, and polyps being 15.4, 14.7, and 55.2 per 1,000 persons, respectively. Older individuals showed significantly higher rates of high-risk events ( Conclusion: MCCG has acceptable detection rates for high-risk events associated with gastric cancer. However, as an alternative diagnostic tool, it lacks biopsy capability, which requires sequential flexible gastroscopy for suspicious lesions. Serologic CAG was significantly associated with MCCG-detected CAG and demonstrated high specificity, suggesting its potential utility in a screening algorithm. Both the screening efficacy of MCCG and the cost-effectiveness of sequential serology-MCCG protocol require further prospective investigation against an appropriate reference standard.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.